返回 
加入收藏
依达拉奉联合马来酸桂哌齐特治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 依达拉奉联合马来酸桂哌齐特治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察依达拉奉联合马来酸桂哌齐特治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的临床疗效及安全性。方法：选择动脉瘤性蛛网膜下腔出血后脑血管痉挛患者66例，采用随机数字表法分为对照组和治疗组，各33例。在常规治疗基础上，对照组患者给予马来酸桂哌齐特注射液320 mg加入0.9％氯化钠注射液500 mL中，ivgtt，qd；治疗组患者在对照组基础上加用依达拉奉注射液30 mg加入0.9％氯化钠注射液100 mL中，ivgtt，bid。两组患者均治疗14 d。比较两组患者治疗前后炎症因子[白细胞介素6（IL-6）和肿瘤坏死因子α（TNF-α）]水平、大脑中动脉收缩峰流速（MCA Vp）、临床疗效及不良反应发生情况。结果：治疗前，两组患者IL-6、TNF-α、MCA Vp水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者IL-6、TNF-α水平和MCA Vp显著降低，且治疗组显著低于对照组，差异均有统计学意义（P＜0.05）。治疗组患者临床总有效率为90.91％，显著高于对照组的63.64％，差异有统计学意义（P＜0.05）。两组患者均未见明显不良反应发生。结论：依达拉奉联合马来酸桂哌齐特治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛疗效显著，能有效降低患者的MCA Vp，减轻炎症反应，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy and safety of edaravone combined with cinepazide maleate in the treatment of cerebral vasospasm （CVS） after aneurismal subarachnoid hemorrhage （SAH）. METHODS： 66 patients with CVS after aneurismal SAH were selected and divided into control group and treatment group according to random number table， with 33 cases in each group. Control group was given Cinepazide maleate injection 320 mg added into 0.9％ Sodium chloride injection 500 mL， ivgtt， qd， on the basis of coventional treatment； treatment group was additionally given Edaravone injection 30 mg added into 0.9％ Sodium chloride injection 100 mL， ivgtt， bid. Both groups were treated for 14 d. Inflammatory factors （IL-6， TNF-α） levels， peak systolic velocity of middle cerebral artery （MCA Vp） before and after treatment， clinical efficacy and the occurrence of ADR were compared between 2 groups. RESULTS： Before treatment， there was no statistical significance in the levels of IL-6， TNF-α and MCA Vp between 2 groups （P＞0.05）； after treatment， the levels of IL-6 ， TNF-α and MCA Vp were decreased significantly in 2 groups， and the treatment group was significantly lower than the control group， with statistical significance （P＜0.05）. Total effective rate of treatment group was 90.91％， which was significantly higher than 63.64％ of control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Edaravone combined with cinepazide maleate has significant therapeutic efficacy on CVS after aneurismal SAH， and can effectively reduce the MCA Vp and inflammatory reaction with good safety. |
| 期刊： | 2017年第28卷第2期 |
| 作者： | 冯怡墨，孙晓川，张晓冬，程泽沛 |
| AUTHORS： | FENG Yimo，SUN Xiaochuan，ZHANG Xiaodong，CHENG Zepei |
| 关键字： | 动脉瘤性蛛网膜下腔出血；脑血管痉挛；马来酸桂哌齐特；依达拉奉 |
| KEYWORDS： | Aneurismal subarachnoid hemorrhage； Cerebral vasospasm； Cinepazide maleate； Edaravone |
| 阅读数： | 281 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
